We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

5,000
Open access books available

124,000
International authors and editors

140M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Chapter 2

Chromatin Structure and Intellectual Disability Syndromes

Adrienne Elbert and Nathalie G. Bérubé

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/55730

1. Introduction

The molecular complex consisting of DNA and its associated proteins is referred to as chromatin. In the central nervous system (CNS), dynamic chromatin remodelling is required for cell division, specification, differentiation, maturation and to respond appropriately to environmental cues (reviewed in 1-4). Modifications to chromatin can act as a form of cellular memory, storing information about a cell’s development, differentiation and environment [5].

In humans, the cerebral cortex is required for normal memory, information processing, thought, attention, perception and language. It consists of six horizontal layers of excitatory pyramidal neurons interspersed with inhibitory interneurons that form distinct synaptic circuits. During synaptic transmission, neurotransmitters released by a neuron bind receptors and initiate electrical signals that travel through the axon of the neighbouring neuron, and in this process alter its morphology and behaviour. One of these modifiable neuronal behaviours is the strength of the synaptic response, termed synaptic plasticity. The complex morphological and gene expression changes that are triggered by synapse formation must be maintained so that the maturing neuron can develop its identity and specific role in the nervous system. Dynamic changes in chromatin structure and gene expression underlie many of the above processes. Perhaps not surprisingly, many neurodevelopmental syndromes characterized by intellectual disabilities are caused by mutations in chromatin modifying factors. In this chapter, we provide an overview of the basic concepts behind chromatin structure regulation, followed by the description of three neurodevelopmental syndromes where altered chromatin structure is believed to be a major causative factor: Cornelia de Lange, Rett and ATR-X syndromes. We highlight common features at the phenotypic and molecular level and discuss the implications for the design of therapies.
2. Basic concepts in chromatin organization and structure

The packaging of DNA into chromatin occurs at different levels. In the primary structure of chromatin, a stretch of DNA is tightly wrapped around four pairs of positively charged structural proteins called histones. Together, the DNA and histones form the basic unit of chromatin known as the nucleosome [6]. In the secondary structure, the nucleosomal array is tightly coiled into a 30 nm chromatin fiber, although whether this arrangement exists in vivo has been questioned [7, 8]. The tertiary structure of chromatin consists of higher order chromatin fibre configurations. The density of chromatin packaging, and its dynamic remodelling, affect the accessibility of the DNA to factors involved in DNA replication, transcription and repair [9]. The molecular determinants that influence the level of compaction of chromatin fibres include DNA methylation, nucleosome composition, histone post-translational modifications (PTMs), ATP-dependent chromatin remodelers, and architectural chromatin-associated proteins.

Methylation of DNA in mammals occurs at cytosine residues, in the context of CpG dinucleotides [10]. DNMT3A and DNMT3B are methyltransferases responsible for de novo methylation [11]. Accordingly, they are responsible for the wave of de novo DNA methylation that occurs in the early embryo [12]. Another enzyme, DNMT1, maintains DNA methylation patterns by acting on newly synthesized DNA to match the parental strand after DNA replication [13-15]. High levels of DNA methylation seem to be correlated with gene inactivity [16]. DNA methylation is involved in gene and transposon silencing [17, 18] and also constitutes the molecular mark that often distinguishes the two alleles of imprinted genes [19-21]. However, DNA methylome analyses in several species have revealed that methylated cytosine residues are also highly enriched in the exons of transcribed genes [22-25]. While the role of exonic DNA methylation is not yet resolved, evidence suggests that it could aid the spliceosome in the process of defining exons [26, 27]. Several derivatives of 5-methylcytosine have now been identified including 5-hydroxymethylcytosine (5-hmc), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). They are thought to be generated during the 5-methylcytosine demethylation pathway catalyzed by the Ten-eleven translocation (Tet) enzymes [28-30]. Interestingly, 5-hmc is most abundant in the brain, especially in the hypothalamus and cerebral cortex [31], and its genomic distribution in human and mouse brain showed that it is greatest at synaptic genes and intron-exon boundaries, suggesting an important function in gene splicing and synaptic activity in the central nervous system [32].

The canonical nucleosome consists of pairs of the four core histones H2A, H2B, H3 and H4. Histone H1 binds the DNA between nucleosomes, which is known as linker DNA, and stabilizes higher order chromatin folding [33-36]. During developmental processes such as gene imprinting and X chromosome inactivation, the canonical histones in the nucleosome can be replaced by atypical forms to designate chromosomal regions for specific functions (reviewed in [37, 38]). For instance, the largest of the histones, MacroH2A, acts as a strong transcriptional repressor [39]. It is found in heterochromatin and is associated with the inactive X chromosome in females and the inactive allele of imprinted genes[40-44]. H2A.Z is typically found at transcriptional start sites of active and inactive genes, and is thought to be involved
in regulating nucleosome positioning [45-50]. H3.3 incorporation into nucleosomes can remove histone H1 from linker DNA and is thought to facilitate recognition of target sequences by the CCCTC-binding (CTCF) zinc finger protein [51]. Moreover, nucleosomes containing both H2A.Z and H3.3 are particularly labile and often correspond to binding sites for CTCF [52, 53].

Post-translational modifications to core and variant histones are crucial for the dynamic changes in chromatin organization [54, 55]. The amino terminal tails of histones that protrude from the nucleosome core can be marked by methylation, acetylation, ubiquitination and phosphorylation, among a growing list of chemical modifications. These marks are introduced or removed by “writer” and “eraser” proteins, respectively, and are recognized by specific “readers” that alter chromatin properties [54]. For example, histone acetylation is catalyzed by writer enzymes called histone acetyltransferases (HATs) that help open chromatin and correlate with transcriptional activation [56-59]. Conversely, transcription repressor complexes often include histone deacetylases (HDACs) that repress transcription by removing acetyl groups from the histones, promoting a closed chromatin state[60]. Bromodomain-containing proteins are reader proteins that specifically bind to acetylated histones [61]. Methylation marks on histones can be repressive, such as H3K9me3 and H3K27me3 [62-64] or they can denote particular regulatory elements. For example H3K4me3 often flags active gene promoters, which is the start-site of gene transcription [65, 66].

The positioning and density of nucleosomes along the DNA influences many cellular processes, including gene transcription [67]. A shift in nucleosome location can expose regulatory sequences of DNA that contain recognition sites for transcription factors or other regulatory proteins. Nucleosome positioning in vivo is dictated by the DNA sequence, the structure of neighbouring chromatin, transcription factors, transcriptional elongation machinery and ATP-dependent chromatin remodeling proteins [67-69]. The displacement of nucleosomes is controlled by protein complexes containing histone chaperones and ATP-dependent nucleosome remodellers. These complexes bind specific histones via the chaperone, and harvest energy from ATP using the ATPase to introduce or displace histones (reviewed in [70]). One example is the Swi/Snf-like ATPase called ATRX that forms a complex with the Daxx histone chaperone to incorporate the histone variant H3.3 into telomeric chromatin [71, 72]. ATRX is known to be involved in human cognition, as mutations in the gene cause intellectual disabilities [73, 74].

Architectural proteins are involved in organizing DNA in the three dimensional space of the cell nucleus [75]. Regulatory sequences like enhancers bind transcription activating protein complexes that interact with distant transcription machinery at the gene promoter through chromatin looping [76, 77]. These chromatin conformations are specific to cell-type and developmental context, as they depend on which transcription and chromatin-associated factors are available in the cell. The activation effect of an enhancer can be blocked by what is known as an insulator sequence. In eukaryotes, CTCF is the only protein known to bind insulator sequences to elicit this blocking effect [78]. CTCF-bound insulators function via the formation of a physically different looping structure, in which the regulatory element can no longer encounter the gene promoter [79, 80]. This type of long-range chromatin fibre interac-
Cohesin also involves the cohesin ring complex, which is believed to encircle DNA strands, as well as ATP-dependent chromatin remodelling proteins [81-83].

Cohesin is a ring complex composed of four proteins: SMC1, SMC3, RAD21 and SA1/SA2 and is genetically conserved from fungi to humans [84]. The ring structure of the complex is formed by interactions between SMC1, SMC3 and RAD21 [85]. The fourth component (either SA1 or SA2) attaches to the ring through interaction with RAD21 and targets cohesin to specific genomic sites [86]. Cohesin and CTCF binding sites largely overlap across the genome, especially near active genes [83, 87]. The current model proposes that CTCF is targeted to its consensus sequence, and cohesin is recruited to the same sites via the SA1/2 subunit [88]. There are now multiple studies demonstrating that cohesin cooperates with CTCF in the formation and stabilization of chromatin looping structures to alter gene expression, including studies at the H19/1gf2 locus [89], the IFNG locus [90], the Beta-globin locus [91], and the MHC class II locus [92]. Depletion of either CTCF or cohesin at these sites results in altered loop formation. In addition, CTCF and cohesin have been demonstrated to mediate interactions of genes and elements on different chromatin fibres [93]. However, cohesin may have a CTCF-independent role in tissue-specific enhancer interactions (reviewed in [94]). A study of murine embryonic stem cells revealed that cohesin localized to a subset of active promoters with a transcriptional coactivator called Mediator, in the absence of CTCF. These genes were expressed in embryonic stem cells through enhancer-promoter interactions that were formed through cohesin-mediator complexes [95]. Cohesin is also required for homologous-recombinational repair of DNA damage following DNA replication [96]. Subunits of cohesin become SUMOylated upon exposure to DNA damaging agents or presence of DNA double-strand breaks by the SUMO E3 ligase Nse2, a subunit of the related Smc5-Smc6 complex [97]. Cohesin was also shown to antagonize binding of the histone variant γH2AX at double-stranded breaks, which may allow for the chromatin remodelling necessary for DNA repair [98].

Normal development and maturation of the human brain relies heavily on the dynamic nature of chromatin and therefore on many of the factors mentioned above. In the next few sections, we discuss particular examples of human disorders with overlapping phenotypes, where mutation of chromatin structure regulators leads to birth defects and intellectual disability (Figure 1).

3. Cornelia de Lange syndrome

Cornelia de Lange Syndrome (CdLS) is a multi-organ developmental disorder characterized by intellectual disability, distinct facial features, growth impairment, short stature and upper limb defects (reviewed in [99]). CdLS causes birth defects in both males and females, and occurs in 1/10,000 to 1/100,000 live births [100, 101]. Clinical manifestations of CdLS range substantially (reviewed in [102, 103]. Facial features and intellectual disability tend to occur in all patients, but limb malformations of the upper extremities present in approximately one third of CdLS patients and range from oligodactyly to absent forearm [104]. About one quarter of patients are affected by a congenital heart defect [105-107] or cleft...
Gastrointestinal abnormalities, diaphragmatic hernia and ambiguous genitalia have also been reported [105, 108, 109].

Central nervous system abnormalities in CdLS include cognitive delay, seizures, self-injurious behaviour, obsessive-compulsive behaviours, attention deficit disorder with or without hyperactivity, and depression. The incidence of structural brain anomalies is unknown, but cerebellar abnormalities have been reported in rare cases [108]. Mild to moderate cases of CdLS are commonly reported to have features of autism [99].

CdLS is caused by mutations in the components of the cohesin complex or its regulatory proteins (reviewed in [84]). Cohesin is responsible for keeping sister chromatids linked during mitosis and meiosis, a process termed sister chromatid cohesion, until they are pulled apart into separating daughter cells (reviewed in [110]). However, abnormal cell division does not satisfactorily explain the molecular cause of CdLS, as only a small fraction of cells from less than
half of CdLS patient-derived cell lines show defects in sister chromatid cohesion [111]. Rather, accumulating evidence suggests that a deregulation of gene expression is likely to be the biggest contributor to the symptoms in CdLS [112, 113].

Haploinsufficiency for \textit{NIPPED-B-LIKE} (\textit{NIPBL}) is the most frequent cause of CdLS, with \textit{NIPBL} gene mutations occurring in more than half of all cases [114-116]. \textit{NIPBL} is a highly conserved protein that facilitates cohesin loading onto DNA [117]. The causative mutations tend to occur \textit{de novo}, and a single mutant allele is sufficient to result in the most common autosomal dominant form of CdLS [118]. Mutations in \textit{SMC1A} and \textit{SMC3}, which belong to the family of structural maintenance of chromosomes proteins, account for an additional 5-10% of CdLS cases [119]. Recently, histone deacetylase 8 (HDAC8) was identified as the vertebrate protein responsible for the deacetylation of SMC3 and the dissolution of the cohesin complex at anaphase [120]. Loss-of-function mutations in \textit{HDAC8}, an X-linked gene, were identified in six of 154 individuals affected by CdLS, including two females [120]. \textit{HDAC8} mutations were also identified in 7 males of a Dutch family affected by a novel syndrome characterized by intellectual disability, hypogonadism, obesity, short stature and distinct facial features reminiscent of Wilson-Turner Syndrome (WTS) [121]. Together the findings from this and the Deardorf et al study suggest that WTS may be an X-linked variant of CdLS, or that CdLS and WTS share a causative molecular pathway.

Mice carrying one mutant copy of \textit{Nipbl} have characteristic features of CdLS including facial anomalies, small size, behavioural disturbances and heart defects [113]. Modest changes in the expression of hundreds of genes were reported in both the mutant mice and in CdLS cell lines [113]. This suggests that perhaps the combination of many small changes in expression culminates into the observed pathology. Experimental manipulation of NIPBL target genes in a zebrafish model indeed revealed additive and synergistic interactions on phenotypic outcomes [112]. Similarly, a lymphoblastic cell line generated from one of the CdLS patients with an \textit{HDAC8} mutation showed that the gene expression profile was strongly correlated with that seen in \textit{NIPBL} mutant cell lines, and not cell lines from control individuals [120]. Gene expression profiling of \textit{Nipbl} mutant embryonic brain tissue revealed a marked down-regulation of the Protocadherin-beta (\textit{Pcdh-β}) genes [113]. In mice, the \textit{Pcdh-α}, -β, and -γ genes are arranged in tandem arrays on chromosome 18 [122]. The clustered \textit{Pcdh} genes comprise >50 putative synaptic recognition molecules that are related to classical cadherins and highly expressed in the nervous system. They are located at both pre- and post-synaptic terminals, making them ideal participants in synapse formation. Only a small subset of protocadherins are expressed in each neuron from the time they are born and a combinatorial effect of protocadherin expression is generated by alternative splicing and promoter usage and is postulated to instruct future synaptic connections and shape the brain’s neuronal circuitry [123, 124]. A similar effect on \textit{Pcdh-β} was reported in the SA1-null embryonic brain, and also in CTCF-null pyramidal neurons [113, 125]. SA1 is largely responsible for cohesin accumulation at promoters and at sites bound by CTCF, emphasizing the linkage between these proteins and their importance for normal protocadherin gene expression in the brain [126].

NIPBL might regulate gene expression by controlling loading and unloading of cohesin onto chromatin, thus counteracting its insulating functions [127]. However, it can also recruit
HDAC1 and HDAC3, suggesting that it may promote chromatin remodelling in this way, leading to gene silencing [128]. Genome-wide analysis of DNA methylation in cell lines derived from CdLS patients show specific methylation patterns that differ from controls, specifically on the X chromosome [129]. It is not clear why DNA methylation is affected in CdLS and whether this impacts gene expression changes seen in the disorder.

4. Rett syndrome (RTT)

Rett syndrome (RTT) is a neurodevelopmental disorder characterized by intellectual disability, autistic features, increased risk of epilepsy, and a loss of previously achieved motor and language milestones. RTT affects about one girl in 10,000-15,000, making it the second leading cause of intellectual disability in females, after Down syndrome [130]. In 1999, Amir et al found that RTT was caused by mutations of the Methyl-CpG-binding protein 2 gene (MeCP2) [131]. RTT is mainly sporadic and the majority of mutations appear to be of paternal origin. Mutations alter protein sequence or result in truncated versions of MeCP2 with residual function [131]. Males carry only a single copy of the MeCP2 gene due to its location on the X chromosome. Since at least one functional copy of the gene is required, males with mutations in MeCP2 are rarely affected with RTT but rather exhibit severe encephalopathy [132-134]. In a typical course of the disease, RTT patients experience normal development up to 6-18 months of age, followed by a period of arrested developmental progress and eventual regression with poor social contact and finger skills (reviewed in 135). In early childhood, the majority of patients have gastrointestinal problems including difficulty swallowing, which likely contributes to malnutrition and pervasive growth problems [136]. In addition, about half of patients have head circumferences below the 3rd percentile (microcephaly), curvature of the spine (scoliosis), and are unable to walk [137].

Much debate still surrounds the question of MeCP2 function at the molecular level, perhaps due to the confounding effects of various post-translational modifications of the protein. MeCP2 is an intrinsically disordered protein that binds methylated DNA via the methyl-binding domain (MBD). One of the roles ascribed to MeCP2 is that of a transcription repressor that binds methylated gene promoters and recruits repressive factors including HDAC1, HDAC2 and Sin3A [138]. For example, recruitment of this complex by MeCP2 regulates the expression of brain-derived neurotrophic factor (BDNF), a protein with important roles in neuronal survival and synaptic plasticity (reviewed in [139]). Neuronal activity leads to demethylation of the Bdnf gene, dissociation of the MeCP2-HDAC complex, and increased gene transcription [140, 141].

Despite this somewhat satisfying and simple model of MeCP2 function as a transcriptional repressor, identification of over-expressed target genes in MeCP2-deficient tissue has been difficult. Even more unsettling was the discovery that half of the genes with MeCP2 bound within the promoter in wild type brain actually showed decreased expression in MeCP2-null tissues [142]. The explanation for these discrepancies may come from emerging data indicating that MeCP2 may regulate the organization and compaction of chromatin at a more global level.
A study by Skene et al. proposed that MeCP2 does not act only in a locus-specific manner, but displays a histone-like distribution across the genome in neurons [143]. Moreover, they found large-scale chromatin changes in neurons of MeCP2-null mice, including elevated histone H3 acetylation and doubling of histone H1 in chromatin. Supporting data comes from in vitro studies of MeCP2, showing that it can induce compaction-related changes in nucleosome architecture that resemble the classical zigzag motif induced by histone H1 and considered important for 30-nm-fiber formation. The doubling of histone H1 in MeCP2-null neurons may be explained by the finding of Ghosh et al, which suggests that MeCP2 competes with H1 for common binding sites [144]. Consistent with a broader role in chromatin structure organization, MeCP2 is homologous to the attachment region binding protein (Arbp) gene in chicken, which has roles in chromatin looping [145]. ARBP has high affinity for specific DNA sequences known as MAR/SARs which it organizes onto a nuclear matrix scaffold [146]. This suggests that ARBP, and by extension perhaps also MeCP2, is involved in chromatin loop organization. MeCP2 loss-of-function was indeed shown to rearrange chromatin fibre interactions at the Dlx5 locus in mouse brain cells using the chromatin conformation capture technique [147]. These results may be highly relevant to RTT pathology given that the DLX5 protein is an important regulator of GABAergic interneuron development [148]. GABAergic signalling plays a vital role in modulating the activity of the cerebral cortex, and alterations in interneuron position and/or migration have been linked to mental retardation, autism, schizophrenia, epilepsy and Down syndrome [149]. Two GABAergic interneuron-specific MeCP2 knockout mouse lines were generated that exhibited reduced GABA levels in their cortices and displayed repetitive behaviours reminiscent of RTT, including hindlimb clasping, forelimb stereotypies and over-grooming leading to fur loss. In addition, these GABA-specific MeCP2 knockout mice showed progressive motor dysfunction [150].

The methyl binding domain (MBD) of MeCP2 targets the protein to methylated DNA and allows for clustering of pericentric heterochromatin in vivo [151]. Analysis of 21 RTT patient mutations showed that two thirds of these decreased the ability of MeCP2 to cluster heterochromatin in mouse cells [152]. This led to the question whether heterochromatin aggregation is impaired in these mutants because of the inability to bind methylated DNA or because of a different function of MeCP2. MeCP2 has multiple chromatins-interacting domains as well as a methylation-independent DNA binding domain in vitro [153]. There was some evidence suggesting that the ability of MeCP2 to control chromatin condensation did not require methylated DNA [147, 154, 155], but it was a study by Casas-Delucchi et al that demonstrated that the role of MeCP2 in heterochromatin condensation was independent of DNA binding [156]. They designed an assay in which different mutant MeCP2 proteins from RTT patients were artificially targeted to heterochromatic regions in living cells by fusion to a heterochromatin-binding protein. This allowed for the effects of MeCP2 mutants on chromatin dynamics and organization to be observed in vivo. Some RTT mutations led to exclusive decreases in methylated DNA binding, without influencing the ability of MeCP2 to cluster heterochromatin, while other mutations affected both functions. In those mutants that were able to cluster heterochromatin, fusion of large heterochromatic structures (over several micrometers in size) were visualized in vivo, providing evidence for the ability of MeCP2 to mediate large-scale chromatin rearrangements [156].
Several mutant mouse models have been generated to study the effects of MeCP2 deficiency (reviewed in [157]). Each RTT model strain has a slightly different time of adverse phenotype onset, but the males usually begin displaying abnormal behaviours between 4-6 weeks after birth. The defects observed in these strains of mice generally recapitulate the symptoms of RTT female patients: laboured breathing, reduced exploratory activity, seizures, cognitive deficits and decreased synaptic plasticity [157-160]. RTT mice clasp their hind paws when suspended by the tail, which is a common sign of neurological deficits [161]. They also have decreased brain weight, smaller cortical neurons with increased neuronal cell density, and reduced dendritic arborisation compared with controls [162, 163]. Importantly, transgenic mice that overexpress MeCP2 also exhibit behaviours of anxiety and impairments in learning and memory, demonstrating that neurons are highly susceptible to either decreased or increased levels of MeCP2.

Several studies provide clues as to the cause of intellectual disability seen in RTT patients. Some of the findings show deficits in long-term potentiation and long-term depression and reduction in spontaneous neurotransmission in cortical and hippocampal neurons of MeCP2-null mice [164-167]. Furthermore, post-mortem tissue displays immature neuronal dendrite morphology predicted to result from altered synaptic activity [162, 168, 169].

5. Alpha-Thalassemia, mental Retardation X-linked syndrome (ATR-X)

ATR-X syndrome is a rare genetic disorder characterized by moderate to severe intellectual and motor disability, mild alpha-thalassemia in a subset of cases, as well as specific developmental abnormalities including facial, skeletal and urogenital defects [170, 171]. ATR-X syndrome affects very few individuals as it frequently results from familial mutations in the ATRX gene on the X chromosome that are passed on to sons by carrier females. In 2009, there were over 200 known male patients [172]. Females are rarely affected due to skewed X chromosome inactivation, in which the X chromosome carrying the mutant ATRX gene is preferentially selected for condensation [173, 174].

Manifestation of ATR-X syndrome can be quite variable [175, 176]. Typically, affected males have severe global delay from birth, developing very little language and motor abilities. Approximately one third of patients have seizures, and microcephaly is not uncommon (reviewed in [177]). These patients also often have gastrointestinal abnormalities, including difficulty swallowing and gastro-esophageal reflux, which has been known to cause death by asphyxiation in multiple ATR-X cases [178]. Some patients have anatomical abnormalities that can cause stomach torsion or cause severe constipation [178]. Genital abnormalities exist in about 80% of cases, and can present as undescended testes, hypospadias, ambiguous genitalia or normal female genitalia [177].

ATR-X syndrome is caused by mutations in the X-linked ATP-dependent chromatin remodelling protein called ATRX [73]. Mutations in the ATRX gene have also been identified in previously characterized mental retardation disorders: Juberg-Marsidi syndrome [179], Carpenter-Waziri syndrome [180], Smith-Fineman-Myers [176] and X-linked mental retarda-
tion with spastic paraplegia [181]. These disorders were mistakenly thought to be distinct from ATR-X syndrome, as there were mild differences in patient presentations. Identification of ATRX mutations in these cases exemplifies the clinical variation that can occur in ATR-X syndrome.

The ATRX mutations identified to date alter protein sequence or code for truncated forms of ATRX, resulting in reduced protein function or protein level [73, 182]. Nearly all of these mutations are found within the two functional domains of ATRX, located at the end termini of the protein [73, 182, 183]. The domain located at the N-terminus is known as the ADD (ATRX-DNMT3-DNMT3L) domain [184]. It consists of DNA-binding zinc fingers, a protein-binding plant homeodomain finger, and a globular region [185]. The ADD domain is a histone H3-binding module that is selective for the combinatorial readout of H3K9 trimethylation and the lack of H3K4 trimethylation [186, 187]. The domain located at the C-terminus displays ATPase and helicase activity, and is homologous to protein regions found in Swi2 / Snf2 family members. This region allows for Swi2/Snf2 proteins to modulate histone-DNA interactions using energy from ATP hydrolysis [188]. ATRX protein-interactions are consistent with a role in chromatin regulation as ATRX has been shown to interact with HP1α [189, 190], EZH2 [191], Mecp2 [155, 192], Daxx [193, 194] and cohesin [155]. Together, the domain analyses and protein interactions of ATRX suggest a role in ATP-dependent alteration of chromatin. ATRX interacts with EZH2 at repetitive sites in centromeres, telomeres and at ribosomal DNA to control heterochromatin formation [195-197]. Heterochromatin formation is further induced by the interaction of ATRX with HP1, a protein that functions in binding and maintaining heterochromatic marks like trimethylated lysine 9 of histone 3 (H3K9Me3) and trimethylated lysine 20 of histone 4 (H4K20Me3) [198].

Forebrain-specific deletion of ATRX causes increased p53-dependent neuronal apoptosis, resulting in reduced forebrain size and hypocellularity of the cortex and hippocampus [199, 200]. Many of the mutant mice die in the neonatal period of unknown causes. In contrast, mice expressing a truncated form of ATRX (ATRX(ΔE2) mice) survive and reproduce normally [201]. Behavioural analyses of these mice showed that they have defects in contextual fear memory with dysfunction of calcium/ calmodulin-dependent protein kinase II (CaMKII) and GluR1 [201]. Further studies showed abnormally increased CaMKII activity in the prefrontal cortex of the ATRX(ΔE2) mice [202]. In addition, their prefrontal cortex contained neurons with longer and thinner dendritic spines than those found in controls, which is consistent with other mouse models of intellectual disabilities [202].

Previous work has also shown that genes are deregulated in cells of ATR-X patients and ATRX mutant mice [203, 204]. Two possible mechanisms by which ATRX can act as a transcriptional regulator have been demonstrated [193, 205]. The presence of Daxx relieves the repressive effect of ATRX, but not through alteration of its ATPase activity [193]. This is now understood to occur through the role of Daxx as a chaperone for histone variant H3.3, a marker of active chromatin. Daxx assists in H3.3-H4 tetramer deposition at nucleosomes at PML nuclear bodies, ribosomal DNA, pericentric DNA and telomeres [71, 206]. One theory is that ATRX directs Daxx to deposit H3.3 at specific chromatin regions that have been made accessible by ATRX through ATP-dependent remodelling. ATRX also acts as an inhibitor of macroH2A deposition.
into chromatin [205]. In ATRX-null cells, macroH2A accumulates at the HBA gene cluster and leads to reduced α-globin expression [205]. This is thought to contribute to the symptom of α-thalassemia seen in ATR-X syndrome patients.

The mechanism by which ATRX may be able to direct Daxx to specific sites is unknown. One possibility is that ATRX localizes to specific loci through the ADD domain [186, 187, 207]. The ADD domain of ATRX was shown to contain two binding pockets for histone 3 modifications: one for unmodified lysine 4 and the other for trimethylated lysine 9 [207]. The combination of these two histone 3 marks is associated with heterochromatin / silent gene promoters and methylated DNA (reviewed in [208]). This combinatorial binding is required for ATRX localization in vivo [207]. Further, mutations in ATRX that disrupt the interaction of the ADD domain with H3K9me3 cause a loss of ATRX targeting to heterochromatin [187].

The localization of ATRX to H3K9me3 is strengthened by interaction with HP1α, which also binds H3K9me3 [207]. In addition, ATRX has been shown to be recruited by Mecp2 [192], which binds the methylated DNA associated with these histone modifications. In fact, loss of MeCP2 in mice results in a loss of ATRX localization at heterochromatic sites in neurons [192]. In addition, a subset of RTT patient MeCP2 mutations interfere with ATRX-MeCP2 interaction [192], which suggests that RTT can be caused in some cases by the inability of MeCP2 to recruit ATRX to specific chromatin sites.

Recently, a family was identified with two men affected by concomitant duplication of both MeCP2 and ATRX [209]. These men did not exhibit signs of ATRX duplication syndrome (short stature, and hypoplastic genitalia), but instead presented with severe mental retardation, muscular hypotonia, and other characteristic features of MeCP2 duplication syndrome. This finding supports the idea that MeCP2 acts upstream of ATRX. However, there was an added feature (cerebellar atrophy) in these patients that was inconsistent with Mecp2 duplication syndrome, which suggests that ATRX may have some additive effect, and not always function in a pathway with MeCP2.

We previously reported that ATRX, MeCP2 and cohesin might cooperate in transcriptional regulation in the brain [155]. In this study, we utilized mice that lack the ATRX protein specifically in the forebrain, by Cre-loxP recombination [199]. These mice have reduced cortical and hippocampal size, reduced number of GABAergic interneurons and exhibit gene expression changes [199, 200, 203]. In control mice, we could show that ATRX and MeCP2 localize to the maternal allele of the H19 imprinted gene at the upstream imprinting control region (H19 ICR). In the absence of ATRX, H19 gene repression in the postnatal period was lessened and correlated with reduced occupancy of cohesin and CTCF at the H19 ICR. These findings suggest that ATRX is required for optimal gene repression through the recruitment of CTCF and cohesin or by promoting their stable binding to chromatin. A link between ATRX and chromatin cohesion was not only found in the context of gene regulation, but also during mitosis and meiosis. Depletion of ATRX protein in human somatic cells resulted in several mitotic defects, such as mis-congression, reduced cohesion and condensation, mis-segregation of chromosomes and the formation of micronuclei [210]. Abnormal chromosome congression and segregation may in part explain the reduced brain size of forebrain-specific ATRX knockout mice [210].
Genome wide assessment of ATRX protein binding was performed in mouse embryonic stem cells and human erythroblast cells [195]. ATRX binding was often seen at high GC-rich regions of the genome, including the telomeres. These DNA sequences have a high probability of forming unusual DNA structures called G-quadruplexes, or G4-DNA, and recombinant ATRX protein was able to bind these structures in vitro. G-quadruplex structures are believed to influence many cellular processes such as transcription elongation and DNA replication and could prove to be an important feature in understanding CNS defects caused by the loss of ATRX protein activity.

6. Therapeutic implications

The shared phenotypic features of CdLS, RTT and ATR-X syndrome (Figure 1) in combination with the molecular findings that place cohesin, MeCP2 and ATRX together in the same physical and functional context (Figure 2) suggest that these three syndromes are in part due to aberration of the same molecular pathways. In particular, the shared feature of intellectual disability and the joint role of MeCP2, ATRX and cohesin in chromatin organization demonstrate that the regulation of chromatin structure is essential for the development of the brain and its complex functions. The study of chromatin structure regulation in the brain, and the identification of defects in gene expression that are caused as a result of abnormal chromatin organization, have been valuable not only to our understanding of human syndromes, but also to the development of therapeutics. This has been especially true of MeCP2 and RTT, the most studied of the three syndromes.

One interesting feature of RTT is that MeCP2-null neurons in the brain do not undergo programmed cell death, or apoptosis[211]. In fact, mounting evidence suggest that RTT is not a neurodegenerative disease, but rather a disorder of neuronal activity (reviewed in [212]). The changes in synaptic maturation and neuronal activity are in part a result of impaired chromatin regulation. Chromatin modifications are dynamic and reversible, which led to the hypothesis that RTT defects may be reversible as well. In 2007, Guy et al. demonstrated that activation of MeCP2 expression in adult MeCP2-deficient mice, even at an advanced stage of illness, reversed neurological symptoms [213, 214]. Replication studies have also shown reversal of RTT morphological features, including neuronal size and dendritic complexity, as well as improvement in functional RTT symptoms such as respiratory function, grip strength and rotarod performance, with the reactivation of MeCP2 in mice [215]. These results have since revolutionized the way in which intellectual disability syndromes are understood [212, 216].

However, there are many obstacles for which gene therapy cannot currently be considered in RTT patients (reviewed in [217]). Gene dosage is one important consideration; since MeCP2 is located on the X chromosome, the number of neurons affected in each patient is dependent on X-inactivation. Providing excess MeCP2 to neurons that already express the non-mutant allele has negative consequences on brain function. This has been observed in mice [214], as well as in humans where severe intellectual disability caused by MeCP2 duplication has been documented (MeCP2 Duplication Syndrome [134, 218, 219]). Therefore a specific dose of the
gene is required. This issue is not unique to MeCP2; over-expression of ATRX in mice led to disorganization of the cells in the brain at the ventricular zone, seizures and death soon after birth [220]. Case studies in humans report that ATRX duplication is associated with severe intellectual disability, genital anomalies and short stature [221, 222].

Due to these and other issues, therapeutic approaches in RTT have had to focus on pathways downstream of MeCP2. The understanding of how MeCP2 perturbs gene expression through its effects on chromatin has been indispensable to these advances. For example, a link between MeCP2 and the regulation of Brain-derived neurotrophic factor (BDNF) expression led Tsai et al. to test the administration of BDNF on the phenotypic outcomes of MeCP2 mutant mice [223, 224]. BDNF is a secreted factor of the neurotrophin family that promotes survival of neurons but also growth and differentiation of new neurons and synapses. BDNF injection led to a slower progression of disease in the RTT mouse model. Potentially, intravenous injection of BDNF in RTT patients could increase BDNF levels in the brain and slow the progression of symptoms. In particular, breathing dysfunction leads to increased mortality and morbidity in
RTT. Reduced levels BDNF in the brain of mice is associated with increased tachypneas and apneas [225-228]. Pharmacological activation of the BDNF receptor TrkB in RTT mice restored wild-type breathing, which demonstrates another potential avenue for therapy in RTT [225]. However, the treatment with the most promise in current literature is the administration of Insulin-like Growth Factor 1 (IGF-1). IGF-1 is an important regulator of synaptic plasticity and maturation that is widely expressed in the brain (reviewed in [229]). Multiple studies have supported the hypothesis that dendritic spines are altered in RTT, implicating synaptic maturation as a major deficit. Treatment of RTT model mice with IGF-1 N-terminal tripeptide, known as GPE, partially restores dendrite spine number, and improves the cortical plasticity levels to that of wild type mice [230]. In addition, it improves gait and breathing patterns of the MeCP2 mutant mice.

7. Conclusions

Animal models have provided an extensive knowledge about the three syndromes discussed above. However these animal studies cannot recapitulate all of the complexities of human brain disorders. Neurodevelopmental disorders have been difficult to study in humans because of the limited supply of post-mortem brain samples and studying peripheral cells from patients such as lymphocytes is problematic because they do not accurately portray defects of the target tissue [231]. Human induced pluripotent stem cells (iPSCs) are a novel technology that may provide a potential solution to this issue. iPSCs are a type of stem cell that are produced by genetic reprogramming of a differentiated somatic cell [232, 233]. These iPSCs can be derived from healthy individuals or from those afflicted by a genetic condition, and then differentiated into the cell type desired for research. Studies of neuronal cells derived from iPSCs of RTT patients have provided valuable complimentary information to the findings from in vivo animal studies. Specifically, modeling RTT with iPSCs has allowed for medications like IGF1 to be tested for efficacy in human RTT patient neurons [234]. Administration of IGF1 was shown to rescue synaptic defects in this model and is currently in clinical trials for treatment of RTT for which primary outcome measures will be available in 2013 (http://clinicaltrials.gov/ct2/show/record/NCT01253317?term=rett+syndrome). It has not been shown whether IGF1 is affected by ATRX or NIPBL knockdown, or whether similar therapies would be beneficial in ATR-X or Cornelia de Lange syndromes. However, since there is evidence that ATRX, cohesin and MeCP2 function together in regulating gene expression and brain development, it is possible that downstream targets, like IGF1, are similarly affected in all three syndromes.

Although more work remains, the study of chromatin modifiers in brain development have provided insight into inherited forms of intellectual disabilities, as well as target pathways for future clinical interventions. Continued investigation of chromatin regulation in neurological and psychiatric disease will help to identify more commonalities between disorders and further our knowledge of potential treatment avenues.
Acknowledgements

We wish to acknowledge funding for this work from the Canadian Institutes for Health Research (CIHR; MOP93697).

A.E. is the recipient of a CIHR Vanier Scholarship.

Author details

Adrienne Elbert¹,³ and Nathalie G. Bérubé¹,²,³

*Address all correspondence to: nberube@uwo.ca

1 Children’s Health Research Institute and Department of Paediatrics, Western University. Victoria Research Laboratories, London, Canada

2 Department Biochemistry, Western University. Victoria Research Laboratories, London, Canada

3 Schulich School of Medicine and Dentistry, Western University. Victoria Research Laboratories, London, Canada

References

[1] Lyons, M. R, & West, A. E. (2011). Mechanisms of specificity in neuronal activity-regulated gene transcription. Prog Neurobiol, 94, 259-295.

[2] Hu, X. L, Wang, Y, & Shen, Q. (2012). Epigenetic control on cell fate choice in neural stem cells. Protein Cell, 3, 278-290.

[3] Leeb, M, & Wutz, A. (2012). Establishment of epigenetic patterns in development. Chromosoma, 121, 251-262.

[4] Alabert, C, & Groth, A. (2012). Chromatin replication and epigenome maintenance. Nat Rev Mol Cell Biol, 13, 153-167.

[5] Brunner, A.M., Tweedie-Cullen, R.Y., and Mansuy, I.M. 2012. Epigenetic modifications of the neuroproteome. Proteomics 12:2404-2420

[6] Kornberg, R. D. (1974). Chromatin structure: a repeating unit of histones and DNA. Science, 184, 868-871.

[7] Joti, Y, Hikima, T, Nishino, Y, Kamda, F, Hihara, S, Takata, H, Ishikawa, T, & Maeshima, K. (2012). Chromosomes without a nm chromatin fiber. Nucleus 3., 30.
[8] Bian, Q, & Belmont, A. S. (2012). Revisiting higher-order and large-scale chromatin organization. *Curr Opin Cell Biol*, 24, 359-366.

[9] Jackson, V. (1990). In vivo studies on the dynamics of histone-DNA interaction: evidence for nucleosome dissolution during replication and transcription and a low level of dissolution independent of both. *Biochemistry*, 29, 719-731.

[10] Bird, A. P. (1986). CpG-rich islands and the function of DNA methylation. *Nature*, 321, 209-213.

[11] Lyko, F, Ramsahoye, B. H, Kashevsky, H, Tudor, M, Mastrangelo, M. A, Orr-weaver, T. L, & Jaenisch, R. (1999). Mammalian (cytosine-5) methyltransferases cause genomic DNA methylation and lethality in Drosophila. *Nat Genet*, 23, 363-366.

[12] Clouaire, T, & Stancheva, I. (2008). Methyl-CpG binding proteins: specialized transcriptional repressors or structural components of chromatin? *Cell Mol Life Sci*, 65, 1509-1522.

[13] Li, E, Bestor, T. H, & Jaenisch, R. (1992). Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. *Cell*, 69, 915-926.

[14] Gruenbaum, Y, Cedar, H, & Razin, A. (1982). Substrate and sequence specificity of a eukaryotic DNA methylase. *Nature*, 295, 620-622.

[15] Bestor, T. H, & Ingram, V. M. (1983). Two DNA methyltransferases from murine erythroleukemia cells: purification, sequence specificity, and mode of interaction with DNA. *Proc Natl Acad Sci U S A*, 80, 5559-5563.

[16] Yeivin, A, & Razin, A. (1993). Gene methylation patterns and expression. *EXS*, 64, 523-568.

[17] Wu, H, & Zhang, Y. (2011). Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. *Genes Dev*, 25, 2436-2452.

[18] Wu, H, Alessio, D, Ito, A. C, Wang, S, Cui, Z, Zhao, K, Sun, K, Zhang, Y. E, & Genome-wide, Y. analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. *Genes Dev*, 25, 679-684.

[19] Reik, W, Collick, A, Norris, M. L, Barton, S. C, & Surani, M. A. (1987). Genomic imprinting determines methylation of parental alleles in transgenic mice. *Nature*, 328, 248-251.

[20] Swain, J. L, Stewart, T. A, & Leder, P. (1987). Parental legacy determines methylation and expression of an autosomal transgene: a molecular mechanism for parental imprinting. *Cell*, 50, 719-727.

[21] Chaillet, J. R, Vogt, T. F, Beier, D. R, & Leder, P. (1991). Parental-specific methylation of an imprinted transgene is established during gametogenesis and progressively changes during embryogenesis. *Cell*, 66, 77-83.
[22] Choi, J. K. (2010). Contrasting chromatin organization of CpG islands and exons in the human genome. *Genome Biol* 11:R70.

[23] Anastasiadou, C, Malousi, A, Maglaveras, N, & Kouidou, S. (2011). Human epigenome data reveal increased CpG methylation in alternatively spliced sites and putative exonic splicing enhancers. *DNA Cell Biol*, 30, 267-275.

[24] Flores, K. B, Wolschin, F, Allen, A. N, Corneveaux, J. J, Huentelman, M, & Amdam, G. V. (2012). Genome-wide association between DNA methylation and alternative splicing in an invertebrate. *BMC Genomics* 13:480.

[25] Bonasio, R, Li, Q, Lian, J, Mutti, N. S, Jin, L, Zhao, H, Zhang, P, Wen, P, Xiang, H, Ding, Y, et al. (2012). Genome-wide and Caste-Specific DNA Methylyomes of the Ants Camponotus floridanus and Harpegnathos saltator. *Curr Biol*.

[26] Malousi, A, & Kouidou, S. (2012). DNA hypermethylation of alternatively spliced and repeat sequences in humans. *Mol Genet Genomics*, 287, 631-642.

[27] Oberdoerffer, S. (2012). A conserved role for intragenic DNA methylation in alternative pre-mRNA splicing. *Transcription*, 3, 106-109.

[28] Pfafﬁeneder, T, Hackner, B, Truss, M, Munzel, M, Muller, M, Deiml, C. A, Hagemeier, C, & Carell, T. (2011). The discovery of 5-formylcytosine in embryonic stem cell DNA. *Angew Chem Int Ed Engl*, 50, 7008-7012.

[29] He, Y. F, Li, B. Z, Li, Z, Liu, P, Wang, Y, Tang, Q, Ding, J, Jia, Y, Chen, Z, Li, L, et al. (2011). Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. *Science*, 333, 1303-1307.

[30] Ito, S, Shen, L, Dai, Q, Wu, S. C, Collins, L. B, Swenberg, J. A, He, C, & Zhang, Y. (2011). Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. *Science*, 333, 1300-1303.

[31] Munzel, M, Globisch, D, Bruckl, T, Wagner, M, Welzmiiller, V, Michalakis, S, Muller, M, Biel, M, & Carell, T. (2010). Quantification of the sixth DNA base hydroxymethylcytosine in the brain. *Angew Chem Int Ed Engl*, 49, 5375-5377.

[32] Khare, T, Pai, S, Konecivicius, K, Pal, M, Kriukiene, E, Liutkeviciute, Z, Irimia, M, Jia, P, Ptak, C, Xia, M, et al. (2012). hmC in the brain is abundant in synaptic genes and shows differences at the exon-intron boundary. *Nat Struct Mol Biol*, 5.

[33] Shaw, B. R, Herman, T. M, Kovacic, R. T, Beaudreau, G. S, & Van Holde, K. E. (1976). Analysis of subunit organization in chicken erythrocyte chromatin. *Proc Natl Acad Sci U S A*, 73, 505-509.

[34] Whitlock, J. P. Jr., and Simpson, R.T. (1976). Removal of histone H1 exposes a fifty base pair DNA segment between nucleosomes. *Biochemistry*, 15, 3307-3314.

[35] Kornberg, R. D. (1977). Structure of chromatin. *Annu Rev Biochem*, 46, 931-954.
[36] Worcel, A, & Benyajati, C. (1977). Higher order coiling of DNA in chromatin. *Cell*, 12, 83-100.

[37] Gamble, M. J, & Kraus, W. L. (2010). Multiple facets of the unique histone variant macroH2A: from genomics to cell biology. *Cell Cycle*, 9, 2568-2574.

[38] Millau, J. F, & Gaudreau, L. (2011). CTCF, cohesin, and histone variants: connecting the genome. *Biochem Cell Biol.*, 89, 505-513.

[39] Doyen, C. M, An, W, Angelov, D, Bondarenko, V, Mietton, F, Studitsky, V. M, Hamiche, A, Roeder, R. G, Bouvet, P, & Dimitrov, S. (2006). Mechanism of polymerase II transcription repression by the histone variant macroH2A. *Mol Cell Biol.*, 26, 1156-1164.

[40] Pehrson, J.R, Fried, V.A, & Macro, . 2A, a core histone containing a large nonhistone region. *Science* 257:1398-1400.

[41] Costanzi, C, & Pehrson, J. R. (1998). Histone macroH2A1 is concentrated in the inactive X chromosome of female mammals. *Nature*, 393, 599-601.

[42] Costanzi, C, Stein, P, Worrad, D. M, Schultz, R. M, & Pehrson, J. R. (2000). Histone macroH2A1 is concentrated in the inactive X chromosome of female preimplantation mouse embryos. *Development*, 127, 2283-2289.

[43] Choo, J.H, Kim, J.D, Kim, J, & Macro, . 2A1 knockdown effects on the Peg3 imprinted domain. *BMC Genomics* 8:479.

[44] Choo, J. H, Kim, J. D, Chung, J. H,Stubbs, L, & Kim, J. (2006). Allele-specific deposition of macroH2A1 in imprinting control regions. *Hum Mol Genet*, 15, 717-724.

[45] Marques, M, Laflamme, L, Gervais, A. L, & Gaudreau, L. (2010). Reconciling the positive and negative roles of histone H2A.Z in gene transcription. *Epigenetics*, 5, 267-272.

[46] Fan, J. Y, Gordon, F, Luger, K, Hansen, J. C, & Tremethick, D. J. (2002). The essential histone variant H2A.Z regulates the equilibrium between different chromatin conformational states. *Nat Struct Biol.*, 9, 172-176.

[47] Gevry, N, Hardy, S, Jacques, P. E, Laflamme, L, Svetelis, A, Robert, F, & Gaudreau, L. A.Z is essential for estrogen receptor signaling. *Genes Dev.*, 23, 1522-1533.

[48] Guillemette, B, Bataille, A. R, Gevry, N, Adam, M, Blanchette, M, Robert, F, & Gaudreau, L. (2005). Variant histone H2A.Z is globally localized to the promoters of inactive yeast genes and regulates nucleosome positioning. *PLoS Biol* 3:e384.

[49] Kumar, S. V, & Wigge, P. A. (2010). H2A.Z-containing nucleosomes mediate the thermosensory response in Arabidopsis. *Cell*, 140, 136-147.

[50] Thakar, A, Gupta, P, Ishibashi, T, Finn, R, Silva-moreno, B, Uchiyama, S, Fukui, K, Tomschik, M, Ausio, J, & Zlatanova, J. (2009). H2A.Z and H3.3 histone variants affect...
nucleosome structure: biochemical and biophysical studies. *Biochemistry*, 48, 10852-10857.

[51] Braunschweig, U, Hogan, G. J, Pagie, L, & Van Steensel, B. binding is inhibited by histone variant H3.3. *EMBO J*, 28, 3635-3645.

[52] Jin, C, Zang, C, Wei, G, Cui, K, Peng, W, Zhao, K, & Felsenfeld, G. (2009). H3.3/H2A.Z double variant-containing nucleosomes mark 'nucleosome-free regions' of active promoters and other regulatory regions. *Nat Genet*, 41, 941-945.

[53] Fu, Y, Sinha, M, Peterson, C. L, & Weng, Z. (2008). The insulator binding protein CTCF positions 20 nucleosomes around its binding sites across the human genome. *PLoS Genet* 4:e1000138.

[54] Strahl, B. D, & Allis, C. D. (2000). The language of covalent histone modifications. *Nature*, 403, 41-45.

[55] Jenuwein, T, & Allis, C. D. (2001). Translating the histone code. *Science*, 293, 1074-1080.

[56] Imhof, A, Yang, X. J, Ogryzko, V. V, Nakatani, Y, Wolfe, A. P, & Ge, H. (1997). Acetylation of general transcription factors by histone acetyltransferases. *Curr Biol*, 7, 689-692.

[57] Allfrey, V. G, & Mirsky, A. E. (1964). Structural Modifications of Histones and their Possible Role in the Regulation of RNA Synthesis. *Science* 144:559.

[58] Allfrey, V. G, Faulkner, R, & Mirsky, A. E. (1964). Acetylation and Methylation of Histones and Their Possible Role in the Regulation of RNA Synthesis. *Proc Natl Acad Sci U S A*, 51, 786-794.

[59] Brownell, J. E, Zhou, J, Ranalli, T, Kobayashi, R, Edmondson, D. G, Roth, S. Y, & Allis, C. D. (1996). Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. *Cell*, 84, 843-851.

[60] Taunton, J, Hassig, C. A, & Schreiber, S. L.. (1996). A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. *Science*, 272, 408-411.

[61] Dhalluin, C, Carlson, J. E, Zeng, L, He, C, Aggarwal, A. K, & Zhou, M. M. (1999). Structure and ligand of a histone acetyltransferase bromodomain. *Nature*, 399, 491-496.

[62] Rea, S, Eisenhaber, F, Carroll, O, Strahl, D, Sun, B. D, Schmid, Z. W, Opravil, M, Mechtler, S, Ponting, K, Allis, C. P, et al. (2000). Regulation of chromatin structure by site-specific histone H3 methyltransferases. *Nature*, 406, 593-599.

[63] Peters, A. H, Carroll, O, Scherthan, D, Mechtler, H, Sauer, K, Schofer, S, Weipoltshammer, C, Pagani, K, Lachner, M, Kohlmaier, M, et al. (2001). Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. *Cell*, 107, 323-337.
[64] Lachner, M, & Jenuwein, T. (2002). The many faces of histone lysine methylation. *Curr Opin Cell Biol*, 14, 286-298.

[65] Roh, T. Y, Cuddapah, S, Cui, K, & Zhao, K. (2006). The genomic landscape of histone modifications in human T cells. *Proc Natl Acad Sci U S A*, 103, 15782-15787.

[66] Guenther, M. G, Levine, S. S, Boyer, L. A, Jaenisch, R, & Young, R. A. (2007). A chromatin landmark and transcription initiation at most promoters in human cells. *Cell*, 130, 77-88.

[67] Jones, B. (2012). Chromatin: A model for nucleosome positioning. *Nat Rev Genet*.

[68] Jansen, A, Van Der Zande, E, Meert, W, Fink, G. R, & Verstrepen, K. J. (2012). Distal chromatin structure influences local nucleosome positions and gene expression. *Nucleic Acids Res*, 40, 3870-3885.

[69] Yen, K, Vinayachandran, V, Batta, K, Koerber, R. T, & Pugh, B. F. (2012). Genomewide nucleosome specificity and directionality of chromatin remodelers. *Cell*, 149, 1461-1473.

[70] Tyler, J. K. (2002). Chromatin assembly. Cooperation between histone chaperones and ATP-dependent nucleosome remodeling machines. *Eur J Biochem*, 269, 2268-2274.

[71] Lewis, P. W, Elsaesser, S. J, Noh, K. M, Stadler, S. C, & Allis, C. D. (2010). Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. *Proc Natl Acad Sci U S A*, 107, 14075-14080.

[72] Goldberg, A. D, Banaszynski, L. A, Noh, K. M, Lewis, P. W, Elsaesser, S. J, Stadler, S, Dewell, S, Law, M, Guo, X, Li, X, et al. (2010). Distinct factors control histone variant H3.3 localization at specific genomic regions. *Cell*, 140, 678-691.

[73] Gibbons, R. J, Picketts, D. J, Villard, L, & Higgs, D. R. (1995). Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome). *Cell*, 80, 837-845.

[74] Gibbons, R. J, Picketts, D. J, & Higgs, D. R. (1995). Syndromal mental retardation due to mutations in a regulator of gene expression. *Hum Mol Genet 4 Spec (1705-1709)*, 1705-1709.

[75] Luger, K, Dechassa, M. L, & Tremethick, D. J. (2012). New insights into nucleosome and chromatin structure: an ordered state or a disordered affair? *Nat Rev Mol Cell Biol*, 13, 436-447.

[76] Bartkuhn, M, & Renkawitz, R. (2008). Long range chromatin interactions involved in gene regulation. *Biochim Biophys Acta*, 1783, 2161-2166.

[77] Nolis, I. K, Mckay, D. J, Mantouvalou, E, Lomvardas, S, Merika, M, & Thanos, D. (2009). Transcription factors mediate long-range enhancer-promoter interactions. *Proc Natl Acad Sci U S A*, 106, 20222-20227.
[78] Bell, A. C, West, A. G, & Felsenfeld, G. (1999). The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. *Cell*, 98, 387-396.

[79] Hou, C, Zhao, H, Tanimoto, K, & Dean, A. (2008). CTCF-dependent enhancer-blocking by alternative chromatin loop formation. *Proc Natl Acad Sci U S A*, 105, 20398-20403.

[80] Nativio, R, Wendt, K. S, Ito, Y, Huddleston, J. E, Uribe-lewis, S, Woodfine, K, Krueger, C, Reik, W, Peters, J. M, & Murrell, A. (2009). Cohesin is required for higher-order chromatin conformation at the imprinted IGFH19 locus. *PLoS Genet* 5:e1000739., 2.

[81] Phillips, J. E, & Corces, V. G. (2009). CTCF: master weaver of the genome. *Cell*, 137, 1194-1211.

[82] Botta, M, Haider, S, Leung, I. X, Lio, P, & Mozziconacci, J. (2010). Intra- and inter-chromosomal interactions correlate with CTCF binding genome wide. *Mol Syst Biol* 6:426.

[83] Wendt, K. S, Yoshida, K, Itoh, T, Bando, M, Koch, B, Schirghuber, E, Tsutsumi, S, Nagae, G, Ishihara, K, Mishiro, T, et al. (2008). Cohesin mediates transcriptional insulation by CCCTC-binding factor. *Nature*, 451, 796-801.

[84] Dorsett, D, & Krantz, I. D. (2009). On the molecular etiology of Cornelia de Lange syndrome. *Ann N Y Acad Sci*, 1151, 22-37.

[85] Huang, C. E, Milutinovich, M, & Koshland, D. (2005). Rings, bracelet or snaps: fashionable alternatives for Smc complexes. *Philos Trans R Soc Lond B Biol Sci*, 360, 537-542.

[86] Neuwald, A. F, & Hirano, T. (2000). HEAT repeats associated with condensins, cohesins, and other complexes involved in chromosome-related functions. *Genome Res*, 10, 1445-1452.

[87] Parelho, V, Hadjur, S, Spivakov, M, Leleu, M, Sauer, S, Gregson, H. C, Jarmuz, A, Canzonetta, C, Webster, Z, Nesterova, T, et al. (2008). Cohesins functionally associate with CTCF on mammalian chromosome arms. *Cell*, 132, 422-433.

[88] Xiao, T, Wallace, J, & Felsenfeld, G. (2011). Specific sites in the C terminus of CTCF interact with the SA2 subunit of the cohesin complex and are required for cohesin-dependent insulation activity. *Mol Cell Biol*, 31, 2174-2183.

[89] Guibert, S, Zhao, Z, Sjolinder, M, Gondor, A, Fernandez, A, Pant, V, & Ohlsson, R. (2012). CTCF-binding sites within the H19 ICR differentially regulate local chromatin structures and cis-acting functions. *Epigenetics*, 7, 361-369.

[90] Hadjur, S, Williams, L. M, Ryan, N. K, Cobb, B. S, Sexton, T, Fraser, P, Fisher, A. G, & Merkenschlager, M. (2009). Cohesins form chromosomal cis-interactions at the developmentally regulated IFNG locus. *Nature*, 460, 410-413.

[91] Chien, R, Zeng, W, Kawauchi, S, Bender, M. A, Santos, R, Gregson, H. C, Schmiesing, J. A, Newkirk, D. A, Kong, X, Ball, A. R, et al. (2011). Cohesin mediates chromatin...
interactions that regulate mammalian beta-globin expression. *J Biol Chem*, 286, 17870-17878.

[92] Majumder, P, & Boss, J. M. (2011). Cohesin regulates MHC class II genes through interactions with MHC class II insulators. *J Immunol*, 187, 4236-4244.

[93] Ren, L, Shi, M, Wang, Y, Yang, Z, Wang, X, & Zhao, Z. (2012). CTCF and cohesin cooperatively mediate the cell-type specific interchromatin interaction between Bcl11b and Arhgap6 loci. *Mol Cell Biochem*, 360, 243-251.

[94] Ong, C. T, & Corces, V. G. (2011). Enhancer function: new insights into the regulation of tissue-specific gene expression. *Nat Rev Genet*, 12, 283-293.

[95] Kagey, M. H, Newman, J. J, Bilodeau, S, Zhan, Y, Orlando, D. A, Van Berkum, N. L, Ebmeier, C. C, Goossens, J, Rahi, P. B, Levine, S. S, et al. (2010). Mediator and cohesin connect gene expression and chromatin architecture. *Nature*, 467, 430-435.

[96] Oum, J. H, Seong, C, Kwon, Y, Ji, J. H, Sid, A, Ramakrishnan, S, Ira, G, Malkova, A, Sung, P, Lee, S. E, et al. (2011). RSC facilitates Rad59-dependent homologous recombination between sister chromatids by promoting cohesin loading at DNA double-strand breaks. *Mol Cell Biol*, 31, 3924-3937.

[97] McAleenan, A, Cordon-preciado, V, Clemente-blanco, A, Liu, I. C, Sen, N, Leonard, J, Jarmuz, A, & Aragon, L. (2012). SUMOylation of the alpha-kleisin Subunit of Cohesin Is Required for DNA Damage-Induced Cohesion. *Curr Biol*, 22, 1564-1575.

[98] Caron, P, Aymard, F, Iacovoni, J. S, Briois, S, Canitrot, Y, Bugler, B, Massip, L, Losada, A, & Legube, G. (2012). Cohesin protects genes against gammaH2AX Induced by DNA double-strand breaks. *PloS Genet* 8:e1002460.

[99] Nakanishi, M, Deardorff, M. A, Clark, D, Levy, S. E, Krantz, I, & Pipan, M. (2012). Investigation of autistic features among individuals with mild to moderate Cornelia de Lange syndrome. *Am J Med Genet A* 158A:, 1841-1847.

[100] Pearce, P. M, & Pitt, D. B. (1967). Six cases of de Lange’s syndrome; parental consanguinity in two. *Med J Aust.*, 1, 502-506.

[101] Opitz, J. M. (1985). The Brachmann-de Lange syndrome. *Am J Med Genet*, 22, 89-102.

[102] Noor, N, Kazmi, Z, & Mehnaz, A. (2012). Cornelia de Lange syndrome. *J Coll Physicians Surg Pak*, 22, 412-413.

[103] Verma, L, Passi, S, & Gauha, K. (2010). Brachman de Lange syndrome. *Contemp Clin Dent*, 1, 268-270.

[104] Kline, A. D, Krantz, I. D, Sommer, A, Kliewer, M, & Jackson, L. G. FitzPatrick, D.R., Levin, A.V., and Selicorni, A. (2007). Cornelia de Lange syndrome: clinical review, diagnostic and scoring systems, and anticipatory guidance. *Am J Med Genet A* 143A:, 1287-1296.
[105] Jackson, L., Kline, A. D., Barr, M. A., & Koch, S. (1993). de Lange syndrome: a clinical review of 310 individuals. *Am J Med Genet*, 47, 940-946.

[106] Mehta, A. V., & Ambalavanan, S. K. (1997). Occurrence of congenital heart disease in children with Brachmann-de Lange syndrome. *Am J Med Genet*, 71, 434-435.

[107] Chatfield, K. C., Schrier, S. A., Li, J., Clark, D., Kaur, M., Kline, A. D., Deardorff, M. A., Jackson, L. S., Goldmuntz, E., & Krantz, I. D. (2012). Congenital heart disease in Cornelia de Lange syndrome: Phenotype and genotype analysis. *Am J Med Genet A* 158A:, 2499-2505.

[108] Chong, K., Keating, S., Hurst, S., Summers, A., Berger, H., Seaward, G., Martin, N., Friedberg, T., & Chitayat, D. (2009). Cornelia de Lange syndrome (CdLS): prenatal and autopsy findings. *Prenat Diagn*, 29, 489-494.

[109] Cunniff, C., Curry, C. J., Carey, J. C., & Graham, J. M. Jr., Williams, C.A., Stengel-Rutkowski, S., Luttgen, S., and Meinecke, Congenital diaphragmatic hernia in the Brachmann-de Lange syndrome. *Am J Med Genet* 47:1018-1021., 1993.

[110] Mehta, G. D., Rizvi, S. M., & Ghosh, S. K. (2012). Cohesin: A guardian of genome integrity. *Biochim Biophys Acta*, 1823, 1324-1342.

[111] Kaur, M., Descipio, C., Mccallum, J., Yaeger, D., Devoto, M., Jackson, L. G., Spinner, N. B., & Krantz, I. D. (2005). Precocious sister chromatid separation (PSCS) in Cornelia de Lange syndrome. *Am J Med Genet A*, 138, 27-31.

[112] Muto, A., Calof, A. L., Lander, A. D., & Schilling, T. F. (2011). Multifactorial origins of heart and gut defects in nipbl-deficient zebrafish, a model of Cornelia de Lange Syndrome. *PLoS Genet* 9:e1001181.

[113] Kawauchi, S., Calof, A. L., Santos, R., Lopez-burks, M. E., Young, C. M., Hoang, M. P., Chua, A., Lao, T., Lechner, M. S., Daniel, J. A., et al. (2009). Multiple organ system defects and transcriptional dysregulation in the Nipbl(+/-) mouse, a model of Cornelia de Lange Syndrome. *PLoS Genet* 5:e1000650.

[114] Gillis, L. A., Mccallum, J., Kaur, M., Descipio, C., Yaeger, D., Mariani, A., Kline, A. D., Li, H. H., Devoto, M., Jackson, L. G., et al. (2004). NIPBL mutational analysis in 120 individuals with Cornelia de Lange syndrome and evaluation of genotype-phenotype correlations. *Am J Hum Genet*, 75, 610-623.

[115] Krantz, I. D., Mccallum, J., Descipio, C., Kaur, M., Gillis, L. A., Yaeger, D., Jukofsky, L., Wasserman, N., Bottani, A., Morris, C. A., et al. (2004). Cornelia de Lange syndrome is caused by mutations in NIPBL, the human homolog of Drosophila melanogaster Nipped-B. *Nat Genet*, 36, 631-635.

[116] Tonkin, E. T., Wang, T. J., Lisgo, S., Bamshad, M. J., & Strachan, T. (2004). NIPBL, encoding a homolog of fungal Scc2-type sister chromatid cohesion proteins and fly Nipped-B, is mutated in Cornelia de Lange syndrome. *Nat Genet*, 36, 636-641.
Ciosk, R., Shirayama, M., Shevchenko, A., Tanaka, T., Toth, A., & Nasmyth, K. (2000). Cohesin’s binding to chromosomes depends on a separate complex consisting of Scc2 and Scc4 proteins. *Mol Cell*, 5, 243-254.

Schoumans, J., Wincent, J., Barbaro, M., Djureinovic, T., Maguire, P., Forsberg, L., Staaf, J., Thuresson, A. C., Borg, A., Nordgren, A., et al. (2007). Comprehensive mutational analysis of a cohort of Swedish Cornelia de Lange syndrome patients. *Eur J Hum Genet*, 15, 143-149.

Pie, J., Gil-rodriguez, M. C., Ciero, M., Lopez-vinas, E., Ribate, M. P., Arnedo, M., Dear-dorff, M. A., Puisac, B., Legarreta, J., De Karam, J. C., et al. (2010). Mutations and variants in the cohesion factor genes NIPBL, SMC1A, and SMC3 in a cohort of 30 unrelated patients with Cornelia de Lange syndrome. *Am J Med Genet A*, 152A, 924-929.

Deardorff, M. A., Bando, M., Nakato, R., Watrin, E., Itoh, T., Minamino, M., Saitoh, K., Komata, M., Katou, Y., Clark, D., et al. (2012). HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. *Nature*, 489, 313-317.

Harakalova, M., van den Boogaard, M. J., Sinke, R., van Lieshout, S., van Tull, M. C., Duran, K., Renkens, I., Terhal, P. A., de Kovel, C., Nijman, I. J., et al. (2012). X-exome sequencing identifies a HDAC8 variant in a large pedigree with X-linked intellectual disability, truncal obesity, gynaecomastia, hypogonadism and unusual face. *J Med Genet*, 49, 539-543.

Wu, Q., Zhang, T., Cheng, J. F., Kim, Y., Grimwood, J., Schmutz, J., Dickson, M., Noonan, J. P., Zhang, M. Q., Myers, R. M., et al. (2001). Comparative DNA sequence analysis of mouse and human protocadherin gene clusters. *Genome Res.*, 11, 389-404.

Hilschmann, N., Barnikol, H. U., Barnikol-watanabe, S., Gotz, H., Kratzin, H., & Thinnes, F. P. (2001). The immunoglobulin-like genetic predetermination of the brain: the protocadherins, blueprint of the neuronal network. *Naturwissenschaften*, 88, 2-12.

Garrett, A. M., & Weiner, J. A. (2009). Control of CNS synapse development by [gamma]-protocadherin-mediated astrocyte-neuron contact. *J Neurosci*, 29, 11723-11731.

Monahan, K., Rudnick, N. D., Kehayova, P. D., Pauli, F., Newberry, K. M., Myers, R. M., & Maniatis, T. Role of CCCTC binding factor (CTCF) and cohesin in the generation of single-cell diversity of protocadherin-alpha gene expression. *Proc Natl Acad Sci U S A*, 109, 9125-9130.

Remeseiro, S., Cuadrado, A., Gomez-lopez, G., Pisano, D. G., & Losada, A. (2012). A unique role of cohesin-SAI in gene regulation and development. *EMBO J*, 31, 2090-2102.

Dorsett, D. (2004). Adherin: key to the cohesin ring and cornelia de Lange syndrome. *Curr Biol* 14:R, 834-836.
Jahnke, P., Xu, W., Wulling, M., Albrecht, M., Gabriel, H., Gillessen-kaesbach, G., & Kaiser, F. J. (2008). The Cohesin loading factor NIPBL recruits histone deacetylases to mediate local chromatin modifications. *Nucleic Acids Res.*, 36, 6450-6458.

Liu, J., Zhang, Z., Bando, M., Itoh, T., Deardorff, M. A., Li, J. R., Clark, D., Kaur, M., Tatsuro, K., Kline, A. D., et al. (2010). Genome-wide DNA methylation analysis in cohesin mutant human cell lines. *Nucleic Acids Res.*, 38, 5657-5671.

Hagberg, B., Goutieres, F., Hanefeld, F., Rett, A., & Wilson, J. (1985). Rett syndrome: criteria for inclusion and exclusion. *Brain Dev.*, 7, 372-373.

Amir, R. E., Van den Veyver, I. B., Wan, M., Tran, C. Q., Francke, U., & Zoghbi, H. Y. (1999). Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nat Genet.*, 23, 185-188.

Meloni, I., Bruttini, M., Longo, I., Mari, F., Rizzolio, F., Adamo, D., Denvriendt, P., Fryns, K., Toniolo, J. P., & Renieri, A. (2000). A mutation in the rett syndrome gene, MECP2, causes X-linked mental retardation and progressive spasticity in males. *Am J Hum Genet.*, 67, 982-985.

Orrico, A., Lam, C., Galli, L., Dotti, M. T., Hayek, G., Tong, S. F., Poon, P. M., Zappella, M., Federico, A., & Sorrentino, V. (2000). MECP2 mutation in male patients with non-specific X-linked mental retardation. *FEBS Lett.*, 481, 285-288.

Van Esch, H., Bauters, M., Ignatius, J., Jansen, M., Raynaud, M., Hollanders, K., Lugtenberg, D., Bienvenu, T., Jensen, L. R., Geicz, J., et al. (2005). Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. *Am J Hum Genet.*, 77, 442-453.

Adkins, N. L., Georgel, P. T., & Me, . 2: structure and function. *Biochem Cell Biol.*, 89:1-11.

Motil, K. J., Caeg, E., Barrish, J. O., Geerts, S., Lane, J. B., Percy, A. K., Annese, F., Mcnair, L., Skinner, S. A., Lee, H. S., et al. (2012). Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with rett syndrome. *J Pediatr Gastroenterol Nutr.*, 55, 292-298.

Han, Z. A., Jeon, H. R., Kim, S. W., Park, J. Y., & Chung, H. J. (2012). Clinical characteristics of children with rett syndrome. *Ann Rehabil Med.*, 36, 334-339.

Nan, X., Ng, H. H., Johnson, C. A., Laherty, C. D., Turner, B. M., Eisenman, R. N., & Bird, A. (1998). Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. *Nature.*, 393, 386-389.

Balaratnasingam, S., & Janca, A. (2012). Brain Derived Neurotrophic Factor: a novel neurotrophin involved in psychiatric and neurological disorders. *Pharmacol Ther.*, 134, 116-124.
[140] Chen, W. G, Chang, Q, Lin, Y, Meissner, A, West, A. E, Griffith, E. C, Jaenisch, R, & Greenberg, M. E. (2003). Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. *Science*, 302, 885-889.

[141] Martinowich, K, Hattori, D, Wu, H, Fouse, S, He, F, Hu, Y, Fan, G, & Sun, Y. E. (2003). DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. *Science*, 302, 890-893.

[142] Chahrour, M, Jung, S.Y, Shaw, C, Zhou, X, Wong, S.T, Qin, J, Zoghbi, H.Y, & Me, . 2, a key contributor to neurological disease, activates and represses transcription. *Science* 320:1224-1229.

[143] Skene, P. J, Illingworth, R. S, Webb, S, Kerr, A. R, James, K. D, Turner, D. J, Andrews, R, & Bird, A. P. (2010). Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. *Mol Cell*, 37, 457-468.

[144] Ghosh, R.P, Horowitz-Scherer, R.A, Nikitina, T, Shlyakhtenko, L.S, Woodcock, C.L, & Me, . 2 binds cooperatively to its substrate and competes with histone H1 for chromatin binding sites. *Mol Cell Biol* 30:4656-4670.

[145] Weitzel, J. M, Buhrmester, H, & Stratling, W. H. (1997). Chicken MAR-binding protein ARBP is homologous to rat methyl-CpG-binding protein MeCP2. *Mol Cell Biol*, 17, 5656-5666.

[146] Buhrmester, H, Von Kries, J. P, & Stratling, W. H. (1995). Nuclear matrix protein ARBP recognizes a novel DNA sequence motif with high affinity. *Biochemistry*, 34, 4108-4117.

[147] Horike, S, Cai, S, Miyano, M, Cheng, J. F, & Kohwi-shigematsu, T. (2005). Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome. *Nat Genet*, 37, 31-40.

[148] Wang, Y, Dye, C. A, Sohal, V, Long, J. E, Estrada, R. C, Roztocil, T, Lufkin, T, Deisseroth, K, Baraban, S. C, & Rubenstein, J. L. (2010). Dlx5 and Dlx6 regulate the development of parvalbumin-expressing cortical interneurons. *J Neurosci*, 30, 5334-5345.

[149] Hernandez-miranda, L. R, Parnavelas, J. G, & Chiara, F. Molecules and mechanisms involved in the generation and migration of cortical interneurons. *ASN Neuro* 2:e00031.

[150] Chao, H. T, Chen, H, Samaco, R. C, Xue, M, Chahrour, M, Yoo, J, Neul, J. L, Gong, S, Lu, H. C, Heintz, N, et al. (2010). Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. *Nature*, 468, 263-269.

[151] Brero, A, Easwaran, H. P, Nowak, D, Grunewald, I, Cremer, T, Leonhardt, H, & Cardoso, M. C. (2005). Methyl CpG-binding proteins induce large-scale chromatin reorganization during terminal differentiation. *J Cell Biol*, 169, 733-743.
[152] Agarwal, N, Becker, A, Jost, K.L, Haase, S, Thakur, B.K, Brero, A, Hardt, T, Kudo, S, Leonhardt, H, Cardoso, M.C, & Me, . 2 Rett mutations affect large scale chromatin organization. Hum Mol Genet 20:4187-4195.

[153] Nikitina, T, Ghosh, R.P, Horowitz-Scherer, R.A, Hansen, J.C, Grigoryev, S.A, Woodcock, C.L, & Me, . 2-chromatin interactions include the formation of chromatosome-like structures and are altered in mutations causing Rett syndrome. J Biol Chem 282:28237-28245.

[154] Georgel, P. T, Horowitz-scherer, R. A, Adkins, N, Woodcock, C. L, Wade, P. A, & Hansen, J. C. (2003). Chromatin compaction by human MeCP2. Assembly of novel secondary chromatin structures in the absence of DNA methylation. J Biol Chem, 278, 32181-32188.

[155] Kernohan, K. D, Jiang, Y, Tremblay, D. C, Bonvissuto, A. C, Eubanks, J. H, Mann, M. R, & Berube, N. G. (2010). ATRX partners with cohesin and MeCP2 and contributes to developmental silencing of imprinted genes in the brain. Dev Cell, 18, 191-202.

[156] Casas-delucchi, C. S, Becker, A, Bolius, J. J, & Cardoso, M. C. (2012). Targeted manipulation of heterochromatin rescues MeCP2 Rett mutants and re-establishes higher order chromatin organization. Nucleic Acids Res.

[157] Calfa, G, Percy, A. K, & Pozzo-miller, L. (2011). Experimental models of Rett syndrome based on Mecp2 dysfunction. Exp Biol Med (Maywood), 236, 3-19.

[158] Chen, R. Z, Akbarian, S, Tudor, M, & Jaenisch, R. (2001). Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet, 27, 327-331.

[159] Guy, J, Hendrich, B, Holmes, M, Martin, J. E, & Bird, A. (2001). A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet, 27, 322-326.

[160] Collins, A. L, Levenson, J. M, Vilaythong, A. P, Richman, R, Armstrong, D. L, & Noebels, J. L, David Sweatt, J., and Zoghbi, H.Y. (2004). Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum Mol Genet , 13, 2679-2689.

[161] Cochran, K. W, & Allen, L. B. (1970). Simple method of evaluating scrapie in mice. Appl Microbiol, 20, 72-74.

[162] Nguyen, M.V, Du, F, Felice, C.A, Shan, X, Nigam, A, Mandel, G, Robinson, J.K, Ballass, N, & Me, . 2 is critical for maintaining mature neuronal networks and global brain anatomy during late stages of postnatal brain development and in the mature adult brain. J Neurosci 32:10021-10034.

[163] Weng, S. M, Bailey, M. E, & Cobb, S. R. (2011). Rett syndrome: from bed to bench. Pediatr Neonatol , 52, 309-316.
[164] Asaka, Y, Jugloff, D. G, Zhang, L, Eubanks, J. H, & Fitzsimonds, R. M. (2006). Hippocampal synaptic plasticity is impaired in the MeCP2-null mouse model of Rett syndrome. *Neurobiol Dis*, 21, 217-227.

[165] Moretti, P, Levenson, J. M, Battaglia, F, Atkinson, R, Teague, R, Antallffy, B, Armstrong, D, Arancio, O, Sweatt, J. D, & Zoghbi, H. Y. (2006). Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome. *J Neurosci*, 26, 319-327.

[166] Dani, V, S, Chang, Q, Maffei, A, Turrigiano, G. G, Jaenisch, R, & Nelson, S. B. (2005). Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. *Proc Natl Acad Sci U S A*, 102, 12560-12565.

[167] Nelson, E.D, Kavalali, E.T, Monteggia, L.M, & Me, . 2-dependent transcriptional repression regulates excitatory neurotransmission. *Curr Biol* 16:710-716.

[168] Stuss, D.P, Boyd, J.D, Levin, D.B, Delaney, K.R, & Me, . 2 mutation results in compartment-specific reductions in dendritic branching and spine density in layer 5 motor cortical neurons of YFP-H mice. *PLoS One* 7:e31896.

[169] Belichenko, P. V, Wright, E. E, Belichenko, N. P, Masliah, E, Li, H. H, Mobley, W. C, & Francke, U. (2009). Widespread changes in dendritic and axonal morphology in MeCP2-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networks. *J Comp Neurol*, 514, 240-258.

[170] Weatherall, D. J, Higgs, D. R, Bunch, C, Old, J. M, Hunt, D. M, Pressley, L, Clegg, J. B, Bethlenfalvay, N. C, Sjolin, S, Koler, R. D, et al. (1981). Hemoglobin H disease and mental retardation: a new syndrome or a remarkable coincidence? *N Engl J Med*, 305, 607-612.

[171] Gibbons, R. J, Wilkie, A. O, Weatherall, D. J, & Higgs, D. R. (1991). A newly defined X linked mental retardation syndrome associated with alpha thalassaemia. *J Med Genet*, 28, 729-733.

[172] Medina, C. F, Mazerolle, C, Wang, Y, Berube, N. G, Coupland, S, Gibbons, R. J, Wallace, V. A, & Picketts, D. J. (2009). Altered visual function and interneuron survival in Atrx knockout mice: inference for the human syndrome. *Hum Mol Genet*, 18, 966-977.

[173] Gibbons, R. J, Suthers, G. K, Wilkie, A. O, Buckle, V. J, & Higgs, D. R. mental retardation (ATR-X) syndrome: localization to Xq12-q21.31 by X inactivation and linkage analysis. *Am J Hum Genet*, 51, 1136-1149.

[174] Wada, T, Sugie, H, Fukushima, Y, & Saitoh, S. (2005). Non-skewed X-inactivation may cause mental retardation in a female carrier of X-linked alpha-thalassemia/mental retardation syndrome (ATR-X): X-inactivation study of nine female carriers of ATR-X. *Am J Med Genet A*, 138, 18-20.

[175] Gibbons, R. J, & Higgs, D. R. (2000). Molecular-clinical spectrum of the ATR-X syndrome. *Am J Med Genet*, 97, 204-212.
[176] Villard, L, Fontes, M, Ades, L. C, & Gecz, J. (2000). Identification of a mutation in the XNP/ATR-X gene in a family reported as Smith-Fineman-Myers syndrome. *Am J Med Genet*, 91, 83-85.

[177] Gibbons, R. (2006). Alpha thalassaemia-mental retardation, X linked. *Orphanet J Rare Dis* 1:15.

[178] Martucciello, G, Lombardi, L, Savasta, S, & Gibbons, R. J. (2006). Gastrointestinal phenotype of ATR-X syndrome. *Am J Med Genet A*, 140, 1172-1176.

[179] Villard, L, Gecz, J, Mattei, J. F, Fontes, M, Saugier-veber, P, Munnich, A, & Lyonnet, S. (1996). XNP mutation in a large family with Juberg-Marsidi syndrome. *Nat Genet*, 12, 359-360.

[180] Abidi, F, Schwartz, C. E, Carpenter, N. J, Villard, L, Fontes, M, & Curtis, M. (1999). Carpenter-Waziri syndrome results from a mutation in XNP. *Am J Med Genet*, 85, 249-251.

[181] Martinez, F, Tomas, M, Millan, J. M, Fernandez, A, Palau, F, & Prieto, F. (1998). Genetic localisation of mental retardation with spastic diplegia to the pericentromeric region of the X chromosome: X inactivation in female carriers. *J Med Genet*, 35, 284-287.

[182] Gibbons, R. J, Wada, T, Fisher, C. A, Malik, N, Mitson, M. J, Steensma, D. P, Fryer, A, Goudie, D. R, Krantz, I. D, & Traeger-synodinos, J. (2008). Mutations in the chromatin-associated protein ATRX. *Hum Mutat*, 29, 796-802.

[183] Cardoso, C, Lutz, Y, Mignon, C, Compe, E, Depetris, D, Mattei, M. G, Fontes, M, & Colleaux, L. (2000). ATR-X mutations cause impaired nuclear location and altered DNA binding properties of the XNP/ATR-X protein. *J Med Genet*, 37, 746-751.

[184] Picketts, D. J, Tastan, A. O, Higgs, D. R, & Gibbons, R. J. (1998). Comparison of the human and murine ATRX gene identifies highly conserved, functionally important domains. *Mamm Genome*, 9, 400-403.

[185] Argentaro, A, Yang, J. C, Chapman, L, Kowalczyk, M. S, Gibbons, R. J, Higgs, D. R, Neuhaus, D, & Rhodes, D. (2007). Structural consequences of disease-causing mutations in the ATRX-DNMT3-DNMT3L (ADD) domain of the chromatin-associated protein ATRX. *Proc Natl Acad Sci U S A*, 104, 11939-11944.

[186] Iwase, S, Xiang, B, Ghosh, S, Ren, T, Lewis, P. W, Cochrane, J. C, Allis, C. D, Picketts, D. J, Patel, D. J, Li, H, et al. (2011). ATRX ADD domain links an atypical histone methylation recognition mechanism to human mental-retardation syndrome. *Nat Struct Mol Biol*, 18, 769-776.

[187] Dhayalan, A, Tamas, R, Bock, I, Tattermusch, A, Dimitrova, E, Kudithipudi, S, Ragozin, S, & Jeltsch, A. (2011). The ATRX-ADD domain binds to H3 tail peptides and reads the combined methylation state of K4 and K9. *Hum Mol Genet*, 20, 2195-2203.
Richmond, E, & Peterson, C. L. (1996). Functional analysis of the DNA-stimulated ATPase domain of yeast SWI2/SNF2. *Nucleic Acids Res*, 24, 3685-3692.

Berube, N. G, Smeenk, C. A, & Picketts, D. J. (2000). Cell cycle-dependent phosphorylation of the ATRX protein correlates with changes in nuclear matrix and chromatin association. *Hum Mol Genet*, 9, 539-547.

Lechner, M. S, Schultz, D. C, Negorev, D, Maul, G. G, & Rauscher, F. J. rd. (2005). The mammalian heterochromatin protein 1 binds diverse nuclear proteins through a common motif that targets the chromoshadow domain. *Biochem Biophys Res Commun*, 331, 929-937.

Cardoso, C, Timsit, S, Villard, L, Khretchtiansky, M, Fontes, M, & Colleaux, L. (1998). Specific interaction between the XNP/ATR-X gene product and the SET domain of the human EZH2 protein. *Hum Mol Genet*, 7, 679-684.

Nan, X, Hou, J, Maclean, A, Nasir, J, Lafuente, M. J, Shu, X, Kriaucionis, S, & Bird, A. (2007). Interaction between chromatin proteins MECP2 and ATRX is disrupted by mutations that cause inherited mental retardation. *Proc Natl Acad Sci U S A*, 104, 2709-2714.

Tang, J, Wu, S, Liu, H, Strat, R, Barak, O. G, Shiekhattar, R, Picketts, D. J, & Yang, X. (2004). A novel transcription regulatory complex containing death domain-associated protein and the ATR-X syndrome protein. *J Biol Chem*, 279, 20369-20377.

Xue, Y, Gibbons, R, Yan, Z, Yang, D, Mcdowell, T. L, Sechi, S, Qin, J, Zhou, S, Higgs, D, & Wang, W. (2003). The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies. *Proc Natl Acad Sci U S A*, 100, 10635-10640.

Law, M. J, Lower, K. M, Voon, H. P, Hughes, J. R, Garrick, D, Viprakasit, V, Mitson, M, De Gobbi, M, Marra, M, Morris, A, et al. (2010). ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner. *Cell*, 143, 367-378.

Mcdowell, T. L, Gibbons, R. J, Sutherland, H, Rourke, O, Bickmore, D. M, Pombo, W. A, Turley, A, Gatter, H, Picketts, K, Buckle, D. J, et al. (1999). Localization of a putative transcriptional regulator (ATRX) at pericentromeric heterochromatin and the short arms of acrocentric chromosomes. *Proc Natl Acad Sci U S A*, 96, 13983-13988.

Berube, N. G. (2011). ATRX in chromatin assembly and genome architecture during development and disease. *Biochem Cell Biol*, 89, 435-444.

Kourmouli, N, Sun, Y. M, Van Der Sar, S, Singh, P. B, & Brown, J. P. (2005). Epigenetic regulation of mammalian pericentric heterochromatin in vivo by HP1. *Biochem Biophys Res Commun*, 337, 901-907.

Berube, N. G, Mangelsdorf, M, Jagla, M, Vanderluit, J, Garrick, D, Gibbons, R. J, Higgs, D. R, Slack, R. S, & Picketts, D. J. (2005). The chromatin-remodeling protein
ATRX is critical for neuronal survival during corticogenesis. *J Clin Invest*, 115, 258-267.

[200] Seah, C, Levy, M. A, Jiang, Y, Mokhtartzada, S, Higgs, D. R, Gibbons, R. J, & Berube, N. G. (2008). Neuronal death resulting from targeted disruption of the Snf2 protein ATRX is mediated by *J Neurosci* 28:12570-12580, 53.

[201] Nogami, T, Beppu, H, Tokoro, T, Moriguchi, S, Shioda, N, Fukunaga, K, Ohtsuka, T, Ishii, Y, Sasahara, M, Shimada, Y, et al. (2011). Reduced expression of the ATRX gene, a chromatin-remodeling factor, causes hippocampal dysfunction in mice. *Hippocampus*, 21, 678-687.

[202] Shioda, N, Beppu, H, Fukuda, T, Li, E, Kitajima, I, & Fukunaga, K. (2011). Aberrant calcium/calmodulin-dependent protein kinase II (CaMKII) activity is associated with abnormal dendritic spine morphology in the ATRX mutant mouse brain. *J Neurosci*, 31, 346-358.

[203] Levy, M. A, Fernandes, A. D, Tremblay, D. C, Seah, C, & Berube, N. G. (2008). The SWI/SNF protein ATRX co-regulates pseudoautosomal genes that have translocated to autosomes in the mouse genome. *BMC Genomics* 9:468.

[204] Hatton, C. S, Wilkie, A. O, Drysdale, H. C, Wood, W. G, Vickers, M. A, Sharpe, J, Ayyub, H, Pretorius, I. M, Buckle, V. J, & Higgs, D. R. (1990). Alpha-thalassemia caused by a large (62 kb) deletion upstream of the human alpha globin gene cluster. *Blood*, 76, 221-227.

[205] Ratnakumar, K, & Duarte, L. F. LeRoy, G., Hasson, D., Smeets, D., Vardabasso, C., Bonisch, C., Zeng, T., Xiang, B., Zhang, D.Y., et al. (2012). ATRX-mediated chromatin association of histone variant macroH2A1 regulates alpha-globin expression. *Genes Dev*, 26, 433-438.

[206] Drane, P, Ouararhni, K, Depaux, A, Shuaib, M, & Hamiche, A. (2010). The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. *Genes Dev*, 24, 1253-1265.

[207] Eustermann, S, Yang, J. C, Law, M. J, Amos, R, Chapman, L. M, Jelinska, C, Garrick, D, Clynch, D, Gibbons, R. J, Rhodes, D, et al. (2011). Combinatorial readout of histone H3 modifications specifies localization of ATRX to heterochromatin. *Nat Struct Mol Biol*, 18, 777-782.

[208] Hashimoto, H, Vertino, P. M, & Cheng, X. (2010). Molecular coupling of DNA methylation and histone methylation. *Epigenomics*, 2, 657-669.

[209] Honda, S, Satomura, S, Hayashi, S, Imoto, I, Nakagawa, E, Goto, Y, & Inazawa, J. and Japanese Mental Retardation, C. (2012). Concomitant microduplications of MECP2 and ATRX in male patients with severe mental retardation. *J Hum Genet*, 57, 73-77.

[210] Ritchie, K, Seah, C, Moulin, J, Isaac, C, Dick, F, & Berube, N. G. (2008). Loss of ATRX leads to chromosome cohesion and congression defects. *J Cell Biol*, 180, 315-324.
[211] Armstrong, D, Dunn, J. K, Antalfy, B, & Trivedi, R. (1995). Selective dendritic alterations in the cortex of Rett syndrome. J Neuropathol Exp Neurol, 54, 195-201.

[212] Gadalla, K.K, Bailey, M.E, Cobb, S.R, & Me, . 2 and Rett syndrome: reversibility and potential avenues for therapy. Biochem J 439:1-14.

[213] Guy, J, Gan, J, Selfridge, J, Cobb, S, & Bird, A. (2007). Reversal of neurological defects in a mouse model of Rett syndrome. Science, 315, 1143-1147.

[214] Luikenhuis, S, Giacometti, E, Beard, C. F, & Jaenisch, R. (2004). Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc Natl Acad Sci U S A, 101, 6033-6038.

[215] Robinson, L, Guy, J, Mckay, L, Brockett, E, Spike, R. C, Selfridge, J, De Sousa, D, Merusi, C, Riedel, G, Bird, A, et al. (2012). Morphological and functional reversal of phenotypes in a mouse model of Rett syndrome. Brain, 135, 2699-2710.

[216] Cobb, S, Guy, J, & Bird, A. (2010). Reversibility of functional deficits in experimental models of Rett syndrome. Biochem Soc Trans, 38, 498-506.

[217] Gray, S. J. (2012). Gene therapy and neurodevelopmental disorders. Neuropharmacology.

[218] Friez, M. J, Jones, J. R, Clarkson, K, Lubs, H, Abuelo, D, Bier, J. A, Pai, S, Simensen, R, Williams, C, Giampietro, P. F, et al. (2006). Recurrent infections, hypotonia, and mental retardation caused by duplication of MECP2 and adjacent region in Xq28. Pediatrics 118:e, 1687-1695.

[219] Meins, M, Lehmann, J, Gerresheim, F, Herchenbach, J, Hagedorn, M, Hameister, K, & Epplen, J. T. (2005). Submicroscopic duplication in Xq28 causes increased expression of the MECP2 gene in a boy with severe mental retardation and features of Rett syndrome. J Med Genet 42:e12.

[220] Berube, N. G, Jagla, M, Smeenk, C, De Repentigny, Y, Kothary, R, & Picketts, D. J. (2002). Neurodevelopmental defects resulting from ATRX overexpression in transgenic mice. Hum Mol Genet, 11, 253-261.

[221] Lugtenberg, D, De Brouwer, A. P, Oudakker, A. P, Pfundt, R, Hamel, B. C, Van Bokhoven, H, & Bongers, E. M. duplication encompassing the ATRX gene in a man with mental retardation, minor facial and genital anomalies, short stature and broad thorax. Am J Med Genet A 149A:, 760-766.

[222] Cohn, D. M, Pagon, R. A, Hudgins, L, Schwartz, C. E, Stevenson, R. E, & Friez, M. J. (2009). Partial ATRX gene duplication causes ATR-X syndrome. Am J Med Genet A 149A:, 2317-2320.

[223] Tsai, S. J. (2012). Peripheral administration of brain-derived neurotrophic factor to Rett syndrome animal model: A possible approach for the treatment of Rett syndrome. Med Sci Monit 18:HY, 33-36.
Chang, Q, Khare, G, Dani, V, Nelson, S, & Jaenisch, R. (2006). The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. *Neuron*, 49, 341-348.

Schmid, D. A, Yang, T, Ogier, M, Adams, I, Mirakhur, Y, Wang, Q, Massa, S. M, Longo, F. M, & Katz, D. M. B small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of Rett syndrome. *J Neurosci*, 32, 1803-1810.

Balkowiec, A, Kunze, D. L, & Katz, D. M. (2000). Brain-derived neurotrophic factor acutely inhibits AMPA-mediated currents in developing sensory relay neurons. *J Neurosci*, 20, 1904-1911.

Kline, D. D, Ogier, M, Kunze, D. L, & Katz, D. M. (2010). Exogenous brain-derived neurotrophic factor rescues synaptic dysfunction in Mecp2-null mice. *J Neurosci*, 30, 5303-5310.

Kron, M, Reuter, J, Gerhardt, E, Manzke, T, Zhang, W, & Dutschmann, M. (2008). Emergence of brain-derived neurotrophic factor-induced postsynaptic potentiation of NMDA currents during the postnatal maturation of the Kolliker-Fuse nucleus of rat. *J Physiol*, 586, 2331-2343.

Bondy, C. A, & Cheng, C. M. (2004). Signaling by insulin-like growth factor 1 in brain. *Eur J Pharmacol*, 490, 25-31.

Tropea, D, Giacometti, E, Wilson, N. R, Beard, C, Mccurry, C, Fu, D. D, Flannery, R, Jaenisch, R, & Sur, M. (2009). Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. *Proc Natl Acad Sci U S A*, 106, 2029-2034.

Chailangkarn, T, Acab, A, & Muotri, A. R. (2012). Modeling neurodevelopmental disorders using human neurons. *Curr Opin Neurobiol*.

Takahashi, A, Tokunaga, A, Yamanaka, H, Mashimo, T, Noguchi, K, & Uchida, I. (2006). Two types of GABAergic miniature inhibitory postsynaptic currents in mouse substantia gelatinosa neurons. *Eur J Pharmacol*, 553, 120-128.

Takahashi, K, Okita, K, Nakagawa, M, & Yamanaka, S. (2007). Induction of pluripotent stem cells from fibroblast cultures. *Nat Protoc*, 2, 3081-3089.

Marchetto, M. C, Carrameu, C, Acab, A, Yu, D, Yeo, G. W, Mu, Y, Chen, G, Gage, F. H, & Muotri, A. R. (2010). A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. *Cell*, 143, 527-539.
